VASCULAR DEMENTIA MARKET SIZE, EPIDEMIOLOGY, AND MARKET FORECAST - 2034

Vascular Dementia Market Size, Epidemiology, and Market Forecast - 2034

Vascular Dementia Market Size, Epidemiology, and Market Forecast - 2034

Blog Article

“The therapeutic market size for Vascular Dementia in the 7MM was around USD 2,399 million in 2023 and is projected to grow at a CAGR of 4% throughout the study period (2020-2034).”

Vascular dementia is the second most common form of dementia after Alzheimer’s disease, caused by reduced blood flow to the brain, leading to cognitive decline. It often arises due to conditions like stroke, small vessel disease, or chronic vascular damage. The disease primarily affects memory, reasoning, and daily functioning, significantly impacting patients and caregivers.

Vascular Dementia Market Insight


The vascular dementia market is experiencing gradual growth driven by rising disease prevalence, improved diagnostics, and ongoing advancements in research. Currently, there is no approved treatment specifically targeting VaD; management focuses on controlling underlying conditions, such as hypertension, diabetes, and high cholesterol, which exacerbate vascular damage.

Cholinesterase inhibitors, such as donepezil, are often used off-label to manage cognitive symptoms, while antihypertensives and anticoagulants are prescribed to address cardiovascular risk factors. Emerging therapies are targeting the vascular pathology underlying dementia, including neuroprotective agents, anti-inflammatory drugs, and drugs improving cerebral blood flow. Advances in biomarkers and imaging techniques are enhancing early detection and treatment response monitoring, creating opportunities for pharmaceutical development.

Key Vascular Dementia Companies In The Market Landscape:


The key Vascular Dementia companies in the market include - Eisai Inc., Ever Neuro Pharma GmbH, Geny Research Corp, Novartis, Charsire Biotechnology Corp, Merz Pharmaceuticals GmbH LLC, Otsuka Pharmaceutical Co.Ltd, Johnson & Johnson Pharmaceutical Research & Development LLC, and others.

 

Vascular Dementia Epidemiology


Vascular dementia primarily affects older adults, with the risk increasing significantly after the age of 65. Globally, it is estimated that 10-20% of dementia cases are due to vascular dementia, accounting for approximately 6-10 million cases worldwide. Regions with aging populations, such as North America, Europe, and parts of Asia-Pacific, report the highest disease burden. Risk factors like cardiovascular diseases, diabetes, and smoking contribute to the disease's rising prevalence.

In the United States alone, the number of cases is projected to grow steadily as life expectancy increases. Similarly, Europe and Asia-Pacific are expected to experience a surge in cases due to demographic and lifestyle changes.

Vascular Dementia Market Forecast


The vascular dementia market is projected to grow significantly by 2034, driven by increasing prevalence and advancements in treatment. North America and Europe currently dominate the market, while Asia-Pacific is anticipated to see the fastest growth due to improved healthcare access and rising awareness. Continued innovation in drug development and early diagnosis will be critical for addressing unmet medical needs in the vascular dementia landscape.

Scope of the Vascular Dementia Market Report



  • Descriptive Overview: The report provides a comprehensive description of Vascular Dementia, including its causes, signs and symptoms, pathophysiology, diagnosis, and current therapies.

  • Epidemiology and Treatment Insight: Offers detailed insights into the epidemiology and treatment of Vascular Dementia across the 7MM (United States, Europe, and Japan).

  • Current and Emerging Therapies: Includes an extensive review of both existing and emerging therapies for Vascular Dementia, assessing how new treatments may impact the current therapeutic landscape.

  • Market Analysis: Provides a thorough analysis of the Vascular Dementia market, including historical data and forecasts, with a focus on drug outreach in the 7MM.

  • Business Strategy Edge: Equips stakeholders with valuable insights for developing business strategies by understanding the trends driving and shaping the Vascular Dementia market.


Conclusion:


The vascular dementia market is set for significant growth by 2034, driven by rising prevalence, advancements in diagnostics, and emerging therapies. Improved awareness, early detection, and innovative treatments will address unmet needs, enhancing patient care and outcomes, particularly in regions with aging populations and increasing healthcare accessibility.

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

 

Report this page